Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,932 | 0,965 | 24.02. | |
0,946 | 0,964 | 24.02. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.02. | CARMAT: Aeson total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation | 269 | Business Wire | Up to 25% of advanced heart failure patients suffer from pulmonary hypertension
Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant... ► Artikel lesen | |
10.02. | CARMAT Achieves the Milestone of 100 Implants of Its Aeson Total Artificial Heart | 240 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
31.01. | CARMAT Raises a Total of €9.7 Million | 461 | Business Wire | Regulatory News:
NOT FOR DIRECT OR INDIRECT DISTRIBUTION IN THE UNITED STATES OF AMERICA, SOUTH AFRICA, CANADA, AUSTRALIA OR JAPAN
CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer... ► Artikel lesen | |
30.01. | CARMAT Launches a €10 Million Global Offering With €7 Million in Subscription Commitments | 406 | Business Wire | Global Offering composed of a reserved offering for qualified investors and a public offering for retail investors via the PrimaryBid platform
Issue price for new shares set at 0.77 euro... ► Artikel lesen | |
CARMAT Aktie jetzt für 0€ handeln | |||||
29.01. | CARMAT: 2025 Financial Calendar | 262 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
13.01. | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025 | 290 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
08.01. | CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson Artificial Heart and Anticipates Continued Strong Momentum in 2025 | 291 | Business Wire | Over 90 patients have received the Aeson® artificial heart since the first implant in 2013, including 42 in 2024.
2024 Sales of €7 million (a 2.5-fold increase vs 2023).
Cash burn... ► Artikel lesen | |
23.12.24 | CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt | 431 | Business Wire | Buy-back by CARMAT of 2 million shares from Airbus for a symbolic sum of 1 euro. The shares so bought-back will be allocated to the repayment of the Company's financial debt, via their... ► Artikel lesen | |
26.11.24 | Successful first "Aeson European User Meeting", marking an important step in the deployment of CARMAT's artificial heart | 124 | Business Wire | More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart All hospitals taking part in the event confirmed... ► Artikel lesen | |
13.11.24 | CARMAT's Aeson Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe | 623 | Business Wire | Milestone of 30 heart transplants post Aeson® support, passed Strong interest in Aeson® from the medical community: more than 100 European experts will share their experience at the first... ► Artikel lesen | |
30.09.24 | CARMAT Announces the Completion of Its Capital Increase for a Gross Amount of €10.3 Million (Namely 100% of the Initial Offer) | 452 | Business Wire | Continued and significant support from two reference shareholders, for a total amount of €5.5 million Net proceeds of €9.4 million, enabling CARMAT to extend its cash runway until early... ► Artikel lesen | |
18.09.24 | CARMAT Launches a Capital Increase for an Initial Amount of €10.3 Million to Finance Its Activities Until at Least the End of 2024 | 527 | Business Wire | This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis,... ► Artikel lesen | |
12.09.24 | Half of Enrolments Targeted in the EFICAS Study Reached by CARMAT | 408 | Business Wire | Enrolment expected to be completed in the first half of 2025
Publication of study results on 52 patients anticipated at the end 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR)... ► Artikel lesen | |
06.09.24 | CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook | 554 | Business Wire | Half-year sales of €3.3 million, exceeding 2023 full-year sales
20 implants of the Aeson® artificial heart performed in the first half of 2024
17% cash-burn1 reduction compared to... ► Artikel lesen | |
03.09.24 | CARMAT Announces Its Participation in Several Scientific and Investor Conferences during the 2nd Half of 2024 | 482 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
09.07.24 | CARMAT accelerates its sales momentum and reiterates its confidence in its development outlook | 509 | Business Wire | 20 implants of the Aeson artificial heart performed in the first half of 2024
Pace of 4 implants per month in the second quarter
Half-year sales at €3.2 million, higher than the... ► Artikel lesen | |
08.07.24 | CARMAT to Provide a Half-Year Update on July 9, 2024 | 436 | Business Wire | Videoconference in French on July 9, 2024 at 6:00 pm CEST.
To participate, please register by clicking on this link
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of... ► Artikel lesen | |
05.07.24 | CARMAT Secures an Equity Financing Line With Vester Finance | 657 | Business Wire | Flexible financing of up to 3,500,000 shares over 24 months CARMAT to receive immediately €2.2 million under this financing, thus extending the Company's cash runway until the end of September... ► Artikel lesen | |
25.06.24 | CARMAT Announces Updates in Its Governance | 591 | Business Wire | Appointment of Mr. Pierre Bastid as Chairman of the Board of Directors to succeed Mr. Alexandre Conroy, who has resigned for personal reasons Retirement of Mr. André Muller, independent... ► Artikel lesen | |
13.06.24 | CARMAT Announces the Start of the Equitization of the First Tranche of Its EIB Loan | 396 | Business Wire | Equitization of the first tranche of the EIB loan will reduce its repayment in cash and optimize the Company's cash position Set-up of a trust and issuance of share warrants to the trustee... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 36,540 | +0,14 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
19.02.2025 /... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 44,610 | +0,86 % | FMC-Aktie gewinnt 2,87 Prozent (36,0489 €) | Im US-amerikanischen Wertpapierhandel notiert die Aktie von FMC zur Stunde fester. Das Papier notiert gegenwärtig bei 37,67 US-Dollar. Jahreschart der FMC Corp-Aktie, Stand 18.02.2025 Am Aktienmarkt... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 54,50 | -2,22 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Siemens Healthineers, Kerry Group, Capgemini und BHP | © Foto: Daniel Karmann/dpa Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 00:30... ► Artikel lesen | |
CARL ZEISS MEDITEC | 54,80 | +0,46 % | Carl Zeiss Meditec Aktie: Eine objektive Analyse | Die Carl Zeiss Meditec-Aktie zeigte am Handelstag eine bemerkenswerte Volatilität an der Frankfurter Börse. Nach einem Handelsstart bei 55,30 EUR durchlief das Papier verschiedene Handelsphasen, wobei... ► Artikel lesen | |
ECKERT & ZIEGLER | 59,40 | -1,90 % | Große Kursgewinne für den Anteilsschein von Eckert&Ziegler (61,15 €) | Zu den großen Gewinnern an der Börse zählt heute die Eckert&Ziegler-Aktie . Der Kurs der Aktie legt kräftig zu. Jahreschart der Eckert&Ziegler AG-Aktie, Stand 20.02.2025 Grund zur Freude haben Aktionäre... ► Artikel lesen | |
DRAEGERWERK | 55,40 | +0,18 % | Kurs von Dräger fällt ab (55,10 €) | An der deutschen Börse liegt das Wertpapier von Dräger gegenwärtig im Minus. Zuletzt zahlten Investoren für das Wertpapier 55,10 Euro. Die Dräger-Aktie verzeichnet aktuell einen Kursverlust von 2,82... ► Artikel lesen | |
MEDTRONIC | 86,30 | +0,15 % | Medtronic Granted FDA Approval For BrainSense Adaptive Deep Brain Stimulation System For Parkinson's | DUBLIN (dpa-AFX) - Medtronic plc (MDT), healthcare technology firm, announced Monday the U.S. Food and Drug Administration (FDA) approval of BrainSense Adaptive deep brain stimulation (aDBS)... ► Artikel lesen | |
INTUITIVE SURGICAL | 566,00 | +0,18 % | Intuitive Surgical Stock Outlook: Is Wall Street Bullish or Bearish? | ||
UNITEDHEALTH | 440,85 | -0,01 % | Dow Jones verliert 0,29 Prozent - UnitedHealth Group mit größtem Kursverlust (44.415 Pkt.) | Die Aktie von der UnitedHealth Group ist derzeit der größte Verlierer im Dow Jones-Index . Gegenwärtig liegt das Kursbarometer mit 0,29 Prozent im Minus. Am Aktienmarkt in den USA zeigen sich die Investoren... ► Artikel lesen | |
GERRESHEIMER | 81,10 | +1,38 % | EQS-AFR: Gerresheimer AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Gerresheimer AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Gerresheimer AG: Vorabbekanntmachung über... ► Artikel lesen | |
TELADOC HEALTH | 10,868 | -0,11 % | Teladoc Health (NYSE:TDOC) Sees Strong Trading Volume Following Analyst Upgrade | ||
THERMO FISHER | 513,50 | +0,27 % | Thermo Fisher Scientific files for automatic mixed securities shelf | ||
STRATEC | 29,550 | -1,83 % | Stratec-Aktie verliert 2,88 Prozent (32,00 €) | Die Aktie von Stratec notiert heute etwas leichter. Die Aktie kostete zuletzt 32,00 Euro. An der deutschen Börse hat sich heute die Stratec-Aktie zwischenzeitlich um 2,88 Prozent verbilligt. Der Kurs... ► Artikel lesen | |
RHOEN-KLINIKUM | 14,100 | +0,71 % | Praxis ist die beste Schule - Stationsprojekt am RHÖN-KLINIKUM Campus Bad Neustadt | Bad Neustadt a. d. Saale (ots) - Eine Ausbildungsklasse, eine Station, eine große Aufgabe: Vom 08. bis 14. Februar übernahmen 20 Schüler der Berufsfachschule für Pflege der RHÖN-KLINIKUM AG den kompletten... ► Artikel lesen | |
HIMS & HERS HEALTH | 48,790 | -0,53 % | Erhebliches Korrekturpotenzial: Highflyer Hims & Hers: Morgan Stanley senkt nach +500 Prozent den Daumen! | © Foto: Sina Schuldt - picture allianceDie Aktie der Online-Apotheke Hims & Hers hat in den vergangenen Wochen stark an Wert gewonnen. Jetzt hat US-Investmentbank Morgan Stanley die Anteile zurückgestuft.Der... ► Artikel lesen |